JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Cellebrite DI (NASDAQ:CLBT) Stock

Key Points

• JPMorgan Chase & Co. has raised its price target for Cellebrite DI (NASDAQ:CLBT) from $20.00 to $23.00, indicating a potential upside of 28.85% based on current stock prices.
• Several other research firms have mixed ratings, with Needham & Company revising their target down to $18.00, while the consensus rating for the stock remains a "Buy" at an average target price of $21.75.
• Cellebrite DI reported quarterly earnings of <$0.12 EPS>, surpassing estimates and showing an 18.4% increase in revenue year-over-year, with a market cap of $4.27 billion.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) had its target price boosted by stock analysts at JPMorgan Chase & Co. from $20.00 to $23.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective suggests a potential upside of 28.85% from the stock's current price.

Several other research firms have also recently weighed in on CLBT. Needham & Company LLC dropped their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. Lake Street Capital dropped their price target on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, August 15th. Finally, Wall Street Zen cut shares of Cellebrite DI from a "buy" rating to a "hold" rating in a research note on Saturday, September 13th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $21.75.

Cellebrite DI Trading Down 0.7%

Shares of NASDAQ CLBT opened at $17.85 on Wednesday. Cellebrite DI has a 12-month low of $13.10 and a 12-month high of $26.30. The stock has a market cap of $4.27 billion, a PE ratio of -23.49, a P/E/G ratio of 3.27 and a beta of 1.28. The company has a 50-day moving average of $15.57 and a 200 day moving average of $16.93.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $113.28 million during the quarter, compared to analysts' expectations of $112.33 million. During the same quarter in the prior year, the company earned $0.10 EPS. Cellebrite DI's revenue was up 18.4% compared to the same quarter last year. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts forecast that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellebrite DI

A number of hedge funds have recently added to or reduced their stakes in CLBT. T. Rowe Price Investment Management Inc. acquired a new stake in Cellebrite DI during the 1st quarter worth approximately $60,939,000. Invesco Ltd. lifted its position in Cellebrite DI by 122.1% in the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after acquiring an additional 1,811,757 shares during the last quarter. Handelsbanken Fonder AB increased its stake in Cellebrite DI by 749.9% in the first quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock valued at $29,508,000 after purchasing an additional 1,340,000 shares during the period. Voss Capital LP increased its stake in Cellebrite DI by 34.0% in the second quarter. Voss Capital LP now owns 5,150,000 shares of the company's stock valued at $82,400,000 after purchasing an additional 1,306,398 shares during the period. Finally, Phoenix Financial Ltd. increased its stake in Cellebrite DI by 153.5% in the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company's stock valued at $32,232,000 after purchasing an additional 1,219,958 shares during the period. 45.88% of the stock is currently owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.